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Introduction: With the increasing use of recombinant α and β interferon therapy for the treatment of various
disorders, cases of interferon-associated sarcoidosis have been reported in the literature. The majority of these have
been cases of interferon-α-induced sarcoidosis. We present the first case, to the best of our knowledge, of
interferon-induced pulmonary sarcoidosis in a patient whose multiple sclerosis was treated with interferon-β.
Case presentation: We present the case of a 30-year-old Caucasian woman who presented with unusually
persistent bilateral areas of lung consolidation on serial radiographs. Pulmonary sarcoidosis was diagnosed on
transbronchial lung biopsy five months after the initiation of treatment with interferon-β for multiple sclerosis.
Conclusions: Sarcoidosis should be considered in the differential diagnosis of a patient who develops clinical or
radiological pulmonary disease while undergoing interferon therapy. It is important to note that interferon-induced
sarcoidosis, though usually seen in cases with interferon-α, can occur with interferon-β. Neurologists managing
patients with multiple sclerosis should be aware of this association between interferon-β and sarcoidosis and
promptly refer patients developing respiratory symptoms for further investigation.Introduction
Sarcoidosis is a chronic systemic disease characterized by
noncaseating granuloma formation that commonly affects
the lungs. In pulmonary sarcoidosis, typical changes on
plain chest radiography include hilar lymphadenopathy or
reticulonodular infiltrates or both.
The exact etiology of sarcoidosis remains unknown. The
existence of an exaggerated immune response to unknown
antigenic stimuli has been proposed [1]. A number of im-
mune modulators such as interferon-γ have been impli-
cated [2]. In recent years, with the increasing use of
recombinant α and β interferon therapy for the treatment
of various disorders, cases of interferon-associated sar-
coidosis have been reported in the literature. The majority
of these have been cases of interferon-α-induced sarcoid-
osis [3-5]. These are described in detail in the Discussion
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distribution, and reproduction in any mediumWe report the case of a 30-year-old Caucasian woman
who presented with unusually persistent bilateral areas
of lung consolidation on serial radiographs. Pulmonary
sarcoidosis was diagnosed five months after the initiation
of treatment with interferon-β for multiple sclerosis. To
the best of our knowledge, this represents the first case
of interferon-induced pulmonary sarcoidosis in a patient
whose multiple sclerosis was treated with interferon-β.Case presentation
A 30-year-old Caucasian woman presented to hospital with
a three-week history of influenza like symptoms, including
joint and muscle aches, fatigue, fever, rigors and tachycar-
dia. She denied breathlessness or productive cough. She
had already received a course of antibiotics from her gen-
eral practitioner. Her inflammatory markers were normal,
but a chest radiograph showed bilateral patchy areas of
consolidation. She was discharged with a further course of
oral antibiotics for presumed pneumonia.
Her symptoms gradually resolved, but the radiological
abnormalities persisted on serial chest radiographs. SheCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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weeks after her initial presentation.
In the clinic, our patient reported feeling well, apart from
dry cough and tiredness. Her medical history included
childhood asthma, asymptomatic chronic idiopathic urti-
caria, irritable bowel syndrome and multiple sclerosis. She
had been receiving treatment for multiple sclerosis with
interferon-β for the previous five months at a dose of 44μg
subcutaneously three times a week. Concern that the fever
and influenza-like symptoms were possible side effects led
to discontinuation of the interferon therapy, which was not
resumed. She was also taking omeprazole, mebeverine and
amitriptyline. Her family history was relevant for multiple
sclerosis in her sister, hypothyroidism and polymyalgia
rheumatica in her mother and type 2 diabetes mellitus in
her father. She smoked 10 to 15 cigarettes a day. On exam-
ination, she had normal vital signs. There was no lymph-
adenopathy and she did not have any skin lesions. The
results of cardiovascular examination were normal. Respira-
tory examination revealed an area of bronchial breathing
on her left lung, but there was no wheeze or crepitations.
At her initial presentation with presumed pneumonia,
her full blood count, renal and liver function, and calcium
and glucose levels were all normal. She had a C-reactive
protein level of 11mg/L (normal range, less than 5mg/L).
Normal results were found at the clinic for her thyroid func-
tion, an autoimmune screen - including levels of antinuclear
antibodies, extractable nuclear antigen and antineutrophil
cytoplasmic antibody - and her 24-hour urinary calcium
levels. A plain chest radiograph (Figure 1) and a computed
tomography scan of her thorax (Figure 2) are shown.
Pulmonary function testing revealed a forced expiratory
volume in 1 second (FEV1) of 2.8L/sec (95% of predicted
rate), a forced vital capacity (FVC) of 3.56 L (105% of pre-
dicted volume), an FEV1/FVC ratio of 94%, a transfer factor
of the lung for carbon monoxide of 74% of the predictedFigure 1 Plain chest radiograph demonstrating bilateral patchy
air-space consolidation and prominent hilar shadows.capacity, and a carbon monoxide transfer coefficient of 85%
of the predicted value.
On bronchoscopy, the mucosa was fragile and hyperemic.
Fluid from bronchoalveolar lavage was negative for malig-
nancy and infection. Acid-fast bacilli were not detected on
microscopy or culture of the bronchoalveolar lavage speci-
men. A transbronchial lung biopsy specimen showed the
presence of histiocytes, giant cells and noncaseating granu-
lomas (Figure 3), consistent with a diagnosis of pulmonary
sarcoidosis.
Although our patient felt better after the interferon-β
was discontinued, she continued to report fatigue and
persistent dry cough. She had persistent and extensive
bilateral parenchymal changes in her lungs and some de-
gree of impairment in her lung function test, including
reduced transfer factor of the lung for carbon monoxide.
For these reasons, she was started on 40mg of prednisol-
one daily. Within four weeks of treatment, there was sig-
nificant resolution of the radiological abnormalities, her
cough disappeared, and she reported reduced fatigue.
She continued on a reducing regime of steroid therapy
over the following six months and remained well with no
flare-up of sarcoidosis. Her disease course was mild and
resembled that of reported interferon-induced sarcoidosis
cases, as discussed in the following section.
Discussion
Sarcoidosis is a chronic systemic disease characterized by
noncaseating granuloma formation that can affect almost
any organ system and that commonly affects the lungs.
The exact etiology of sarcoidosis remains unknown. An
exaggerated immune response to unknown antigenic stim-
uli is thought to exist. Proposed antigens include infectious
agents, such as mycobacteria, environmental agents and
autoantigens [1]. In sarcoidosis, the affected organs appear
to have a predominance of type 1 T helper cells (cluster of
differentiation 4 T cells) and macrophages, resulting in
granuloma formation. A number of immune modulators,
such as interleukin-2, interleukin-12 and interferon-γ, have
been implicated [2]. Interferon-γ is released from lung T
lymphocytes and alveolar macrophages and activates pul-
monary macrophages, contributing to granuloma forma-
tion [6].
Interferon-γ belongs to the class II interferon family. It
has a different structure and binds to a different receptor
than the class I interferons (α and β), and its gene is located
on a different chromosome [7]. Although interferon-γ has
been implicated in the pathogenesis of sarcoidosis [6], there
is little evidence implicating other types of interferons.
However, there is evidence that exogenously administered
interferon-α and interferon-β can activate macrophages
in vitro [8].
Recombinant interferons (α and β) are used as immu-
nomodulators in the treatment of various conditions,
a b
Figure 2 Computed tomography scan of thorax. (a) Extensive mediastinal and bilateral hilar lymphadenopathy. (b) Multifocal patchy air-space
consolidation in both lungs.
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lignancies such as lymphoproliferative disorders, renal
cell carcinoma and melanoma, and multiple sclerosis
(interferon-β). Adverse reactions to interferon therapy in-
clude non-specific symptoms, such as cough, generalized
malaise, fever and arthralgia, and develop in up to one
third of patients in the first months of treatment [9]. In
addition, various autoimmune processes have developed
in patients treated with interferons [9]. The diverse immu-
nomodulatory effects of exogenously administered inter-
ferons have been reported to upset the balance between
self-tolerance and autoimmunity. With increasing use of
interferon therapy in recent years, cases of interferon-
associated sarcoidosis have been reported in the literature.
To the best of our knowledge, the first pathologically
proven case of interferon-induced sarcoidosis was reported
in 1987 in a woman whose advanced renal cell carcinoma
was treated with interferon-β [10]. Since then, numerous
published cases have suggested a relationship betweenFigure 3 Histology picture of a transbronchial lung biopsy
specimen showing the presence of Langhans-type giant cells
and noncaseating granulomas. Hematoxylin and eosin stain;
magnification ×40.interferon treatment and induction, recurrence or exacerba-
tion of sarcoidosis. Most of the reported cases involve
patients whose hepatitis C infection was treated with pegy-
lated interferon-α (often in combination with ribavirin).
A case series in 1998 reported a 5% incidence of sarcoid-
osis in a cohort of 60 patients whose chronic hepatitis C
infection was treated with interferon-α in a randomized
control trial [3]. In 1999, Pietropaoli et al. [4] published the
case of a 50-year-old woman who developed sarcoidosis
while her chronic myelogenous leukemia was being treated
with interferon-α. What was interesting in that case was
that the authors demonstrated a dose–response effect and
a temporal relationship of the interferon treatment with
sarcoidosis activity, concluding that interferon-α most
likely triggered the manifestations of sarcoidosis in that pa-
tient. In 2006, Goldberg et al. [5] reviewed the literature in
English and found 60 cases of sarcoidosis development
after the institution of recombinant interferon-α therapy.
The majority of patients received interferon-α therapy for
hepatitis C infection, but some were treated for hepatitis B,
lymphoproliferative malignancies and other hematological
conditions. The most commonly affected organs were the
lungs and the skin. The mean onset of development of
sarcoidosis was 11.4 months after initiation of interferon
therapy (range of 1 to 60 months). Interferon therapy was
discontinued in the majority of patients with interferon-
induced sarcoidosis and, as a result, the sarcoidosis resolved
within months. A small proportion of patients received
systemic corticosteroid treatment and had rapid resolution
of the sarcoidosis. Interferon-induced sarcoidosis generally
exhibited a relatively mild disease course. Interestingly, a few
patients in the literature responded to a reduction in the
dose of interferon with resolution of the signs of disease.
It is important to note that interferon-induced sarcoidosis
has been reported in numerous cases with interferon-α
treatment but in only very few with interferon-β. In fact, in
our literature search, we identified only two cases in which
treatment with interferon-β induced sarcoidosis: a woman
with advanced renal cell carcinoma in 1987 [10] and a
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our knowledge, our case report represents the first case of
interferon-induced pulmonary sarcoidosis in a patient
whose multiple sclerosis was treated with interferon-β. It
is important to note that our patient had no medical his-
tory or features of sarcoidosis prior to interferon therapy.
Sarcoidosis was diagnosed five months after the initiation
of interferon-β therapy.
Lastly, it is worth mentioning that bronchiolitis obliter-
ans organizing pneumonia has also been reported after
treatment with interferon-α and interferon-β [12], and
pulmonary infiltrates and eosinophilia with interferon-α
[13]. Indeed, the above differential diagnoses would be
compatible with the clinical presentation of our patient,
but the diagnosis of sarcoidosis was confirmed on trans-
bronchial lung biopsy.Conclusions
Our experience with this case demonstrates that sarcoid-
osis should be considered in the differential diagnosis of
a patient who develops pulmonary disease (clinical or
radiological) while undergoing interferon therapy and
that the diagnosis can usually be confirmed by transbron-
chial lung biopsy. A review of the literature demonstrated
that interferon-induced sarcoidosis exhibits a mild dis-
ease course and most patients have complete resolution
of the disease within a few months of discontinuing
interferon therapy, without the need for immunosup-
pressants. Patients treated with systemic corticosteroids
show rapid disease resolution.
It is important to note that, although interferon-induced
sarcoidosis is usually seen with interferon-α therapy, our pa-
tient developed the condition with interferon-β. Neurologists
managing patients with multiple sclerosis should be aware of
the association between interferon-β and sarcoidosis and
promptly refer patients developing respiratory symptoms for
further investigation.Consent
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